Goldman Sachs Upgrades Myriad Genetics (MYGN) to Buy

Article Stock Quotes (1) Comments (0)

Goldman Sachs upgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Buy with a price target of $29.00 (from $27.00).

The firm cited: (1) we believe the recent reimbursement concerns are overdone and believe that the patent debate does not pose near/medium term risk; (2) MYGN's highly US-focused business offers several new product catalysts; (3) we see potential for improved capital allocation to drive share outperformance in 2H; and (4) we believe the scarcity value of established Diagnostics assets warrants an M&A premium in our price target methodology.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $23.77 yesterday, with a 52 week range of $17.51-$27.00.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
• Goldman Sachs Downgrades InterXion Holding (INXN) to Neutral
• Deutsche Bank Upgrades priceline.com (PCLN) to Buy

Create E-mail Alert Related Categories

Hot Upgrades, Upgrades

Related Entities

Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?